Inflammatory Bowel Disease - 2013
Inflammatory bowel disease (IBD) is a general diagnostic term that describes conditions with idiopathic, chronic, relapsing and remitting inflammation of the gastrointestinal tract. Crohn’s disease (CD) and ulcerative colitis (UC) are the two most common types of IBD. UC is limited to the colon (large intestine).
This document (2013) is a general guide to appropriate practice, to be followed subject to the clinician's judgment and the patient's preference in each individual case in the management of Inflammatory Bowel Disease. The guidelines are designed to provide information to assist in decision making but are not exhaustive, nor do they cover every discrete situation.
They are based on the best evidence available at the time of writing. These guidelines have been peer reviewed and endorsed by the Australian Inflammatory Bowel Disease Association (AIBDA).
The document is intended primarily for the use of clinicians in Australia, while complementing recent consensus statements published by the European Crohn's and Colitis Organisation (ECCO), the British Society of Gastroenterology and other international organisations.
Every effort has been made to check drug dosage recommendations in this guideline but it is still possible that inaccuracies exist. Furthermore, dosage recommendations are continually being revised and new adverse events recognised. Trade names used in this publication are for identification purposes only. Their use does not imply endorsement of any particular brand of drug.
The document has been prepared by the Digestive Health Foundation of the Gastroenterological Society of Australia and every care has been taken in its development. The Gastroenterological Society of Australia and other compilers of these guidelines do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information.
Download GESA Clinical Update: Inflammatory Bowel Disease